40258-99-9Relevant articles and documents
TREATMENT OF CANCER WITH ANTI-OX40 ANTIBODIES AND MULTI-KINASE INHIBITORS
-
Paragraph 0089-0091, (2021/05/29)
The present disclosure provides methods of treating cancer with non-competitive, agonist anti-OX40 antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), in combination with a multi-kinase inhibitor.
Preparation method of cabozantinib nitrogen oxide impurity
-
Paragraph 0025-0026; 0036-0037, (2020/08/27)
The invention discloses a preparation method of a cabozantinib nitrogen oxide impurity. The method comprises the following steps: preparation of an intermediate 1, preparation of 4-chloro-6, 7-dimethoxyquinoline, preparation of an intermediate 2, and prep
METHOD OF PREPARING FLUORINE-18 LABELED CABOZANTINIB AND ITS ANALOGS
-
Paragraph 00102; 00103, (2016/03/29)
The present invention relates to a method of preparing Cabozantinib (Cyclopropane- 1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylo]amide (4-fluoro- phenyl)amide) and 18F labeled Cabozantinib.